Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by 2O2Ovisionon Oct 25, 2023 1:11pm
157 Views
Post# 35700438

RE:RE:RE:Trucchio @Wainwright...

RE:RE:RE:Trucchio @Wainwright...Hey Fox I can't see who you're arguing with but the Sigilon deal is only 35M upfront and seeing as Lily already owned about 9% only costs them 30M net, with milestone for roughly another 300M net. So yeah their shares jumped from just under 4$ to low 20's on the annoucement but if were talking about such low numbers with ONC, it would be something along the lines of a partnership not a buyout. Not saying I wouldn't mind a 5-600% premium lol but I'd be mighty disapointed in that premium for a buyout. But there is a big difference with a company throwing around 30M in a company they're already invested in so hopefully we start getting some traction once the Pancan trial is detailed. I'm holding here until we see a business plan sooner than later but good luck.  
<< Previous
Bullboard Posts
Next >>